ES2486321T3 - Péptidos como agentes activos para estabilizar barreras biológicas - Google Patents
Péptidos como agentes activos para estabilizar barreras biológicas Download PDFInfo
- Publication number
- ES2486321T3 ES2486321T3 ES11732400.4T ES11732400T ES2486321T3 ES 2486321 T3 ES2486321 T3 ES 2486321T3 ES 11732400 T ES11732400 T ES 11732400T ES 2486321 T3 ES2486321 T3 ES 2486321T3
- Authority
- ES
- Spain
- Prior art keywords
- xib1
- thrombin
- lps
- pma
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 title description 3
- 239000013543 active substance Substances 0.000 title 1
- 230000004888 barrier function Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 108090000190 Thrombin Proteins 0.000 description 27
- 229960004072 thrombin Drugs 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 16
- 101100244348 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pma-1 gene Proteins 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003518 stress fiber Anatomy 0.000 description 5
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 4
- 101150111584 RHOA gene Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 230000008497 endothelial barrier function Effects 0.000 description 2
- 230000004890 epithelial barrier function Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004887 epithelial permeability Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT10102010 | 2010-06-18 | ||
| AT10102010 | 2010-06-18 | ||
| PCT/EP2011/060105 WO2011157819A2 (en) | 2010-06-18 | 2011-06-17 | Peptides as active agents to stabilize biological barriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2486321T3 true ES2486321T3 (es) | 2014-08-18 |
Family
ID=44628513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11732400.4T Active ES2486321T3 (es) | 2010-06-18 | 2011-06-17 | Péptidos como agentes activos para estabilizar barreras biológicas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9012403B2 (enExample) |
| EP (1) | EP2582720B1 (enExample) |
| JP (1) | JP5709985B2 (enExample) |
| CN (1) | CN103038253A (enExample) |
| CA (1) | CA2802635A1 (enExample) |
| ES (1) | ES2486321T3 (enExample) |
| RU (1) | RU2012157399A (enExample) |
| WO (1) | WO2011157819A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3459558B1 (en) | 2010-06-25 | 2020-07-29 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| WO2015022326A1 (en) | 2013-08-12 | 2015-02-19 | Xiber Science Gmbh | Peptides as active agents for treating primary graft dysfunction |
| NL2015130B1 (en) * | 2015-07-09 | 2017-02-01 | Mimetas B V | Barrier function measurements. |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| JP7483684B2 (ja) * | 2018-08-17 | 2024-05-15 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 急性肺損傷の処置のための組成物および方法 |
| JP7486497B2 (ja) * | 2019-01-16 | 2024-05-17 | ユニバーシティ オブ ロチェスター | 上皮または内皮バリア機能の改善 |
| EP4093423A1 (en) | 2020-01-22 | 2022-11-30 | UCL Business Ltd | Peptide inhibitors of guanine nucleotide exchange factor-h1 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US20040053250A1 (en) | 2001-03-05 | 2004-03-18 | Tang Y. Tom | Novel arginine-rich protein-like nucleic acids and polypeptides |
| ATE424416T1 (de) * | 2002-07-03 | 2009-03-15 | San Raffaele Centro Fond | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
-
2011
- 2011-06-17 RU RU2012157399/04A patent/RU2012157399A/ru not_active Application Discontinuation
- 2011-06-17 JP JP2013514731A patent/JP5709985B2/ja not_active Expired - Fee Related
- 2011-06-17 CA CA2802635A patent/CA2802635A1/en not_active Abandoned
- 2011-06-17 US US13/702,490 patent/US9012403B2/en not_active Expired - Fee Related
- 2011-06-17 CN CN2011800299272A patent/CN103038253A/zh active Pending
- 2011-06-17 WO PCT/EP2011/060105 patent/WO2011157819A2/en not_active Ceased
- 2011-06-17 EP EP11732400.4A patent/EP2582720B1/en not_active Not-in-force
- 2011-06-17 ES ES11732400.4T patent/ES2486321T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011157819A2 (en) | 2011-12-22 |
| EP2582720A2 (en) | 2013-04-24 |
| WO2011157819A3 (en) | 2012-02-23 |
| JP5709985B2 (ja) | 2015-04-30 |
| EP2582720B1 (en) | 2014-05-21 |
| JP2013529916A (ja) | 2013-07-25 |
| RU2012157399A (ru) | 2014-07-27 |
| CN103038253A (zh) | 2013-04-10 |
| US20130143791A1 (en) | 2013-06-06 |
| CA2802635A1 (en) | 2011-12-22 |
| US9012403B2 (en) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2486321T3 (es) | Péptidos como agentes activos para estabilizar barreras biológicas | |
| Perrotta et al. | Autophagy in the regulation of tissue differentiation and homeostasis | |
| Akins et al. | Axonal ribosomes and mRNAs associate with fragile X granules in adult rodent and human brains | |
| Sala et al. | Dendritic spines: the locus of structural and functional plasticity | |
| Kole et al. | Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush | |
| Cerrato et al. | Novel cell‐penetrating peptide targeting mitochondria | |
| Ivanov | Actin motors that drive formation and disassembly of epithelial apical junctions | |
| Furman et al. | Ena/VASP is required for endothelial barrier function in vivo | |
| Chen et al. | Regulation of sleep by the short neuropeptide F (sNPF) in Drosophila melanogaster | |
| Carmosino et al. | Role of nuclear Lamin A/C in cardiomyocyte functions | |
| Bär et al. | Skin fragility and impaired desmosomal adhesion in mice lacking all keratins. | |
| JP7263667B2 (ja) | 中枢作用性ペプチド誘導体及び医薬組成物 | |
| JP2018521112A (ja) | アルツハイマー病の治療におけるＰＩ４ＫＩＩＩαタンパク質および関連膜タンパク質複合体の利用 | |
| Nahacka et al. | Miro proteins connect mitochondrial function and intercellular transport | |
| CN106632601A (zh) | 一种阻断突触长时程增强（ltp）的短肽及其应用 | |
| ES2397300T3 (es) | Utilización de péptidos de SCO-espondina para inhibir o prevenir la apoptosis neuronal mediada por los ligandos de receptores de la muerte celular | |
| BR112012025092B1 (pt) | Uso de um peptídeo capaz de romper os filamentos intermediários do citoesqueleto em uma célula de mamífero | |
| Jash et al. | Modulation of mitochondrial respiratory capacity by carrier-mediated transfer of RNA in vivo | |
| WO2018215563A1 (en) | Calcineurin b homologous protein 1 inhibitors and therapeutic and non-therapeutic uses thereof | |
| ES2322881B1 (es) | Uso de compuestos agonistas de la actividad pi3k en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas. | |
| US9359404B2 (en) | Methods and products for treating preeclampsia and modulating blood pressure | |
| Ayme-Southgate et al. | In indirect flight muscles Drosophila projectin has a short PEVK domain, and its NH2-terminus is embedded at the Z-band | |
| Rascher | Chemical and pharmacological characterization of terpenoids from Hericium species and other Basidiomycota as neuroregenerative compounds | |
| Mlostek et al. | Dendritic arbor dynamics and stability in health and disease | |
| WO2007135570A2 (en) | Pink1 deficient animals, screening methods, and related therapeutics |